A5035474483- Liver Diseases and Immunity
- Inflammatory Bowel Disease
- Pediatric Hepatobiliary Diseases and Treatments
- Celiac Disease Research and Management
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gallbladder and Bile Duct Disorders
- Biliary and Gastrointestinal Fistulas
- Hepatitis Viruses Studies and Epidemiology
- Therapeutic Uses of Natural Elements
- Urological Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Hepatitis B Virus Studies
- Gastrointestinal disorders and treatments
- Neuroendocrine Tumor Research Advances
- Blood groups and transfusion
- Immunodeficiency and Autoimmune Disorders
- Colorectal Cancer Screening and Detection
- Hepatitis C virus research
- Pancreatic and Hepatic Oncology Research
- Gastrointestinal Tumor Research and Treatment
- Lung Cancer Research Studies
- Drug Transport and Resistance Mechanisms
- Kidney Stones and Urolithiasis Treatments
- Mycobacterium research and diagnosis
- Pelvic floor disorders treatments
University of Birmingham
2025
University Hospitals Birmingham NHS Foundation Trust
2025
NIHR Birmingham Biomedical Research Centre
2025
Cork University Hospital
2023
University College Cork
2023
SGS Germany GmbH (Germany)
2023
Queen Elizabeth Hospital Birmingham
2022-2023
Queen Elizabeth Hospital
2018
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD). The strong association between gut and liver inflammation has driven several pathogenic hypotheses to which intestinal microbiome proposed contribute. Pilot studies faecal microbiota transplantation (FMT) in PSC IBD are demonstrated be safe associated with increased bacterial diversity. However, longevity such changes impact on markers activity progression have not been...
Abstract Background The majority of patients with primary sclerosing cholangitis (PSC) have inflammatory bowel disease (IBD). This association has fostered several pathogenic hypotheses linking mucosal immunity to hepatobiliary inflammation. A putative therapeutic target along this axis centres on gut-derived IL-17 secretor cell subtypes, which are activated by interleukin (IL)23. Notably, emergent forms IBD treatment host anti-IL23 agents, however safety and efficacy data in PSC is limited....
Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in western world. In this article, we present Consensus Statement on LT practice, developed by dedicated Guidelines' Taskforce European Society Organ Transplantation (ESOT). The overarching goal to provide practical guidance commonly debated topics, including indications timing LT, management bile duct stenosis patients...
Hepatitis D virus (HDV), also referred to as hepatitis delta virus, is the smallest capable of causing human disease. It unable replicate on its own and can only propagate in presence B (HBV). Infection with both HBV HDV frequently results more severe disease than alone, higher instances cirrhosis, liver failure hepatocellular carcinoma (HCC). Thus, there a need for effective treatment HDV; however, currently approved options are very limited terms their efficacy availability. This makes...
<h3>Background</h3> Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). In a Phase 3, 12-month (Mo) study (ORAL Standard) including RA patients (pts) on stable background methotrexate (MTX), tofacitinib and adalimumab (ADA) demonstrated significant improvements in efficacy outcomes compared with placebo (PBO).<sup>1</sup> <h3>Objectives</h3> To evaluate ADA based upon American College Rheumatology (ACR) component scores post-hoc analysis ORAL Standard....